Medpace Holdings, Inc. $MEDP Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 164.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,653 shares of the company’s stock after buying an additional 2,274 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Medpace were worth $2,086,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in MEDP. Quent Capital LLC acquired a new position in shares of Medpace during the third quarter worth about $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace during the third quarter worth about $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Quarry LP acquired a new position in shares of Medpace during the third quarter worth about $35,000. Finally, Root Financial Partners LLC acquired a new position in shares of Medpace during the third quarter worth about $38,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported a Q4 beat and raised FY‑2026 earnings guidance (EPS range 16.68–17.50), with revenue and margins improving year‑over‑year — a fundamental driver supporting the stock.
• Neutral Sentiment: Zacks published a comparison piece weighing PACS vs MEDP for value investors; these types of relative‑value writeups can attract attention but don’t directly change company fundamentals. PACS vs. MEDP: Which Stock Is the Better Value Option?
• Neutral Sentiment: Brokerage consensus on Medpace remains a “Hold” per recent aggregation — that suggests analysts are mixed despite solid results, so follow analyst note revisions for directional signals. Medpace Receives Consensus “Hold”
• Negative Sentiment: A wave of law firms has announced investigations and multiple class‑action notices alleging securities law violations tied to disclosures during an April 22, 2025–Feb 9, 2026 class period; several firms are soliciting lead plaintiffs — this increases legal and reputational risk and can pressure the stock. Medpace Shareholders — Contact Law Offices About Securities Fraud Investigation
• Negative Sentiment: An investor filed suit alleging that demand projections were misstated and tied the allegations to a roughly 16% stock decline — a concrete complaint that could lead to litigation costs or settlements if claims advance. Medpace Investor Sues Over Demand Projections

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MEDP shares. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Mizuho set a $582.00 price target on Medpace in a research note on Wednesday, February 11th. Leerink Partners cut their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada started coverage on Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Price Performance

Medpace stock opened at $520.65 on Thursday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The business has a 50 day simple moving average of $476.51 and a 200-day simple moving average of $537.42. The stock has a market capitalization of $14.87 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 2.39 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter in the prior year, the business earned $3.67 earnings per share. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.